If you are unable to see the message below, view the web version.
OPEN Pre–Conference: October 3, 2012
Now Available for ACPE and ANCC Credit!
The business of running an oncology pharmacy is complex and ever-changing. Are you up to date on new treatments and trends?
Dear INSERT_CUSTOM03 INSERT_LAST_NAME,
The Association of Community Cancer Centers' Oncology Pharmacy Education Network's Pre-conference on October 3, 2012, in San Antonio, provides the strategies and information that you need to keep pace and stay competitive. The one-day meeting, "Oncology Pharmacy 2012: New Treatments and Trends," explores pharmacy practice in both the hospital and private practice settings.
This pre-conference to the ACCC 29th National Oncology Conference stands out for its exceptional value and broad range of sessions that will help you and your pharmacy team:
Registration is just $169. If you pay for and attend the full ACCC 29th National Oncology Conference, registration is free.
Take advantage of ACCC's discounted registration fees.
The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of the program includes attending the accredited session(s) and completing a Record of Attendance/Evaluation Form. CPE credit will be issued by The University of Texas at Austin College of Pharmacy Continuing Education Office via CPE Monitor approximately 4-6 weeks following the program. This Knowledge-based activity has been accredited for 0.55 CEUs or 5.5 contact hours.
This activity is eligible for ACPE credit; see final CPE activity announcement for specific details.
The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is offered for a maximum of ANCC 6.0 contact hours.
Target Audience: This pre-conference is designed for oncology pharmacists, pharmacy directors, financial officers, and administrators who contribute to decisions about which drugs should be used for cancer patients.